Title : A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.

Pub. Date : 2020 Aug

PMID : 32336008






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 OBJECTIVES: To assess the efficacy and tolerability of the dual EGFR/VEGFR inhibitor, vandetanib, in combination with carboplatin and gemcitabine in the first line treatment of patients with advanced urolthelial cancer (UC) who were unsuitable for cisplatin. vandetanib kinase insert domain receptor Homo sapiens